Physician profile
Howard Entin
NPI 1679918882
$9,042.25
in general payments reported to CMS, 2019-2025
27 companies · $951 in 2025
The $951 reported for 2025 was more than what 80% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,993 · 2020: $935 · 2021: $1,157 · 2022: $1,481 · 2023: $1,696 · 2024: $829 · 2025: $951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,475.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,411.91 | 2021-2025 | |
| Allergan, INC. | $965.57 | 2019-2020 | |
| Lundbeck LLC | $814.54 | 2019-2025 | Rexulti, Brintellix |
| Neurocrine Biosciences, INC. | $723.43 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $718.98 | 2019-2025 | Lybalvi, Aristada |
| Sunovion Pharmaceuticals INC. | $703.80 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $560.27 | 2020-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $502.82 | 2019-2024 | Nuedexta, Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $483.33 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $470.37 | 2020-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $285.42 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $250.90 | 2022-2024 | Quviviq |
| Avanir Pharmaceuticals, INC. | $190.40 | 2019-2022 | |
| Bausch Health US, LLC | $145.50 | 2019-2024 | Aplenzin |
| Merck Sharp & Dohme LLC | $125.48 | 2020-2023 | Belsomra |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $122.27 | 2019-2021 | |
| Corium, LLC | $120.07 | 2023-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $99.41 | 2019-2024 | Spravato |
| Eisai INC. | $94.48 | 2020-2022 | |
| Shire North American Group INC | $60.12 | 2019 | |
| Neos Therapeutics, LP | $53.21 | 2019-2020 | |
| Brainsway USA INC | $45.01 | 2021 | |
| Ironshore Pharmaceuticals INC. | $21.83 | 2019 | |
| Neuronetics, INC. | $19.55 | 2020 | |
| Alfasigma USA, INC. | $19.52 | 2020 | |
| Supernus Pharmaceuticals, INC. | $19.36 | 2022 | |
| Jazz Pharmaceuticals INC. | $14.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Entin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.